Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VIRACTA THERAPEUTICS, INC.

(SNSS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Viracta Up 5% After It Reacquires Rights to Combination Therapy in China

08/23/2021 | 11:03am EDT

By Michael Dabaie

Viracta Therapeutics Inc. shares were up 5% to $9.51 after the company said it reacquired the rights to its combination therapy in China.

The oncology company targeting virus-associated malignancies said it reacquired the exclusive rights to develop and commercialize its all-oral combination product candidate in China previously licensed to Shenzhen Salubris Pharmaceuticals Co. The rights were returned to Viracta in exchange for a $4 million cash payment to Salubris.

Viracta's combination therapy of nanatinostat and valganciclovir is currently in a Phase 2 trial for Epstein-Barr virus-positive lymphoma.

Viracta also received U.S. Food and Drug Administration clearance of an investigational new drug application for a Phase 1b/2 trial of the combination therapy in EBV(+) recurrent or metastatic nasopharyngeal carcinoma and other EBV(+) solid tumors.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

08-23-21 1102ET

Stocks mentioned in the article
ChangeLast1st jan.
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. 1.34% 27.95 End-of-day quote.-1.34%
VIRACTA THERAPEUTICS, INC. -3.25% 6.26 Delayed Quote.-7.11%
All news about VIRACTA THERAPEUTICS, INC.
10/06VIRACTA THERAPEUTICS : Multinational trial expands Viracta's clinical-stage pipeline beyon..
PU
10/06VIRACTA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/06Viracta Therapeutics Starts Trial of Nanatinostat in Epstein-Barr Virus-Positive Solid ..
MT
10/06Viracta Therapeutics Initiates Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) S..
CI
09/20VIRACTA THERAPEUTICS, INC.(NASDAQGS : VIRX) added to S&P Global BMI Index
CI
09/07VIRACTA : Therapeutics to Present at Upcoming Investor Conferences in September
PR
08/23Viracta Up 5% After It Reacquires Rights to Combination Therapy in China
DJ
08/23VIRACTA THERAPEUTICS : Reacquires Exclusive Rights to Combination Therapy Candidate for Ly..
MT
08/23VIRACTA THERAPEUTICS : Reacquires Exclusive Development and Commercialization Rights for i..
PU
08/23VIRACTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Termination of a ..
AQ
More news
Analyst Recommendations on VIRACTA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2020
Net income 2020
Net Debt 2020
P/E ratio 2020
Yield 2020
Capitalization 241 M 241 M -
EV / Sales 2020
Capi. / Sales 2021 -
Nbr of Employees 20
Free-Float 85,4%
Chart VIRACTA THERAPEUTICS, INC.
Duration : Period :
Viracta Therapeutics, Inc. Technical Analysis Chart | SNSS | US92765F1084 | MarketScreener
Technical analysis trends VIRACTA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 6,47 $
Average target price 33,50 $
Spread / Average Target 418%
EPS Revisions
Managers and Directors
Ivor Royston President, Chief Executive Officer & Director
Daniel R. Chevallard Secretary, Chief Operating & Financial Officer
Roger J. Pomerantz Chairman
Lisa Rojkjaer Chief Medical Officer
Ayman El-Guindy Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
VIRACTA THERAPEUTICS, INC.-7.11%241
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414